Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.90 USD
+0.27 (16.56%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.90 0.00 (0.00%) 7:34 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Earnings News For MRNS
-
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
-
Marinus Pharmaceuticals: Q2 Earnings Snapshot
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
-
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
-
Marinus Pharmaceuticals: Q1 Earnings Snapshot
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
-
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
-
Marinus Pharmaceuticals: Q4 Earnings Snapshot
-
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY? Net Product Revenue and Provides Business Update
-
Marinus Pharmaceuticals: Q3 Earnings Snapshot
-
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
-
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
-
Marinus Pharmaceuticals: Q2 Earnings Snapshot
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
-
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
-
Marinus Pharmaceuticals: Q1 Earnings Snapshot
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
-
Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline
-
Marinus Pharmaceuticals: Q4 Earnings Snapshot
-
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY? Net Product Revenue and Provides Business Update
-
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates